Australia is carefully awaiting the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://jessedbjp148232.wikifrontier.com/9219112/retatrutide_australia_a_new_hope_for_obesity_treatment